Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury—outcomes at 6 months

CRASH trial collaborators *

MRC CRASH is a randomised controlled trial (ISRCTN 74459797) of the effect of corticosteroids on death and disability after head injury. We randomly allocated 10 008 adults with head injury and a Glasgow Coma Scale score of 14 or less, within 8 h of injury, to a 48-h infusion of corticosteroid (methylprednisolone) or placebo. Data at 6 months were obtained for 9673 (96·7%) patients. The risk of death was higher in the corticosteroid group than in the placebo group (1248 [25·7%] vs 1075 [22·3%] deaths; relative risk 1·15, 95% CI 1·07–1·24; p=0.0001), as was the risk of death or severe disability (1828 [36·3%] vs 1728 [36·3%] dead or severely disabled; 1·05, 0·99–1·10; p=0·079). There was no evidence that the effect of corticosteroids differed by injury severity or time since injury. These results lend support to our earlier conclusion that corticosteroids should not be used routinely in the treatment of head injury.

The MRC CRASH trial (corticosteroid randomisation after significant head injury) is a large international double-blind randomised placebo-controlled trial of the effect of early administration of a 48-h infusion of a corticosteroid (methylprednisolone) on the risk of death and disability after head injury.

The background to the trial, methods, and baseline characteristics of the patients randomised have been previously reported in detail. Briefly, we randomly allocated 10 008 adults with head injury and a Glasgow Coma Scale score of 14 or less, within 8 h of injury, to commence either a 48-h infusion of methylprednisolone or matching placebo. The loading dose was 2 g methylprednisolone (or matching placebo) over 1 h in a 100 mL infusion. The maintenance dose was 0·4 g methylprednisolone (or matching placebo) per h for 48 h in a 20 mL per h infusion. Randomisation was achieved either by use of the central telephone randomisation service provided by the Clinical Trial Service Unit in Oxford, UK, or by using a local pack system. In local pack randomisation, the next consecutively numbered treatment pack was taken from a box of eight packs, with an allocation sequence based on a block size of eight, also generated by the Clinical Trial Service Unit. The joint primary outcome measures were death from all causes within 14 days, and death or disability at 6 months. Data on death within 14 days of injury were obtained from a single-sided early outcome form completed at death, discharge, or 14 days after injury, whichever occurred first. Data on deaths after 14 days and within 6 months were obtained by contact with patients’ general practitioners, and by access to death certification records. Before the start of the trial, a simple questionnaire version of the Glasgow Outcome Scale was developed and was shown to provide a reliable and valid assessment of disability. Disability at 6 months was assessed by means of this questionnaire, which was either mailed to patients or their carers, administered by telephone interview, or administered during a home visit or hospital appointment. Treatment allocation remained concealed from patients, carers, and interviewers.

For analysis of outcomes at 6 months, we pre-specified that death, persistent vegetative state, and severe disability on the Glasgow Outcome Scale constituted an unfavourable outcome, whereas moderate disability and good recovery constituted a favourable outcome. We planned to report the effects of treatment overall and also subdivided by two characteristics at baseline: time from injury to randomisation (≤1 h, >1 to ≤3 h, or >3 to ≤8 h) and severity of head injury based on the Glasgow Coma Score at randomisation (severe 3–8, moderate 9–12, mild 13–14). Analyses were done on an intention-to-treat basis. The effect measure used was relative risk with 95% CI for the overall risk and 99% CI for the results of subgroups. Homogeneity in treatment effects within subgroups was assessed with a chi-squared test on two degrees of freedom at a 5% significance level.

This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN 74459797. The protocol for this study was peer-reviewed and accepted by The Lancet; a summary of the protocol was published on the journal’s website.

Follow-up data at 6 months are now available for 9673 (96·7%) patients (table). Of 4854 patients allocated corticosteroids, 1248 (25·7%) died within 6 months of randomisation compared with 1075 (22·3%) of 4819 patients allocated matching placebo, yielding a relative risk of 1·15 (95% CI 1·07–1·24; p=0·0001) as was the risk of death or severe disability (1828 [36·3%] vs 1728 [36·3%] dead or severely disabled; 1·05, 0·99–1·10; p=0·079).

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Corticosteroid allocated (n=5007)</th>
<th>Placebo allocated (n=5001)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number with known vital status</td>
<td>4854 (96·9%)</td>
<td>4819 (96·4%)</td>
</tr>
<tr>
<td>Dead*</td>
<td>1245 (25·7%)</td>
<td>1075 (22·3%)</td>
</tr>
<tr>
<td>Severe disability*</td>
<td>580 (11·9%)</td>
<td>653 (13·6%)</td>
</tr>
<tr>
<td>Moderate disability*</td>
<td>852 (17·6%)</td>
<td>813 (16·9%)</td>
</tr>
<tr>
<td>Good recovery*</td>
<td>2120 (43·3%)</td>
<td>2212 (45·9%)</td>
</tr>
<tr>
<td>Alive (disability status not known)*</td>
<td>54 (1·1%)</td>
<td>65 (1·3%)</td>
</tr>
</tbody>
</table>

*Percentages show proportion of number with known vital status.

Table: Outcomes 6 months after injury by treatment allocation

Published online May 26, 2005
DOI:10.1016/S0140-6736(05)66532-X
*See end of paper
Correspondence to: CRASH Trials Co-ordinating Centre, London School of Hygiene and Tropical Medicine, Keppel St, London WC1E 7HT, UK
crash@lshtm.ac.uk
risk of death within 6 months of 1.15 (95% CI 1.07–1.24; p=0.0001). The risk of death or severe disability at six months was also higher in the group allocated corticosteroids (1828 [38.1%] dead or severely disabled, where disability status was known) than in the placebo group (1728 [36.3%] dead or severely disabled, with a relative risk of 1.05 (95% CI 0.99–1.10; p=0.079).

There was no clear evidence that the relative risk of death or disability at 6 months differed substantially between groups when stratified by injury severity or time since injury (figure). These results reliably refute any risk of death within 6 months of 1.15 (95% CI 1.07–1.24; p=0.0001). The risk of death or severe disability at six months was also higher in the group allocated corticosteroids (1828 [38.1%] dead or severely disabled, where disability status was known) than in the placebo group (1728 [36.3%] dead or severely disabled, with a relative risk of 1.05 (95% CI 0.99–1.10; p=0.079).

The ability to predict patient outcome after head injury has an important role in clinical practice and research, and the data collected in the MRC CRASH trial provide an opportunity to examine prognostic factors after head injury. This assessment will, however, be the subject of a separate report.

CRASH trial collaborators
See webappendix for the complete list of collaborators.

CRASH trial coordination

Data monitoring and ethics committee—Rory Collins, Stephen Haines, Stephen MacMahon (Chair), Charles Warlow (1999–01), Jonathan Wasserberg, David Yates.


Trial coordinating team—Haleema Shakur (trial manager from 2002), Ian Roberts (clinical co-ordinator), Phil Edwards (research fellow/programmer), Maria Ramos (trial administrator), Lin Barnetson (data manager from 2004), Janice Fernandes (follow-up co-ordinator from 2003), Donna Tooth (assistant trial co-ordinator from 2004).
Cari Free (Clinical Research Fellow), Leena Narayanan (assistant programmer from 2003), Johan Collander (trial assistant from 2002), Julia Abernethy (trial assistant from 2004), Josephine Bardswell (team secretary from 2003), Nin Ritchie (trial manager to 2002), Reshma Mashru (data manager to 2004), Catherine Godward (follow-up co-ordinator to 2000), Elizabeth Afolabi (assistant co-ordinator 2001–03), Adrian Ritchie (assistant programmer to 2003), Tessa Hosford (trial assistant 2001–02, assistant trial co-ordinator 2003–04), Sheila Pantrini (UK South nurse co-ordinator 2001 to 2002), Sheila Massey (UK North nurse co-ordinator from 2001), Amber Collingwood (team secretary 2001–03).

Writing committee—Phil Edwards (Chair), Miguel Arango (Colombia), Laura Balca (Romania), Rowland Cottingham (UK), Hesham El-Sayed (Egypt), Barbara Farrell (UK), Janice Fernandes (UK), Tamar Gogichaisvili (Georgia), Nyoman Golden (Indonesia), Bennie Hartzenberg (South Africa), Mazhar Husain (India), Mario Izurieta Ullou (Ecuador), Zouheir Jerbi (Tunisia), Hussein Khamis (Egypt), Edward Komolafe (Nigeria), Véronique Laloë (Sri Lanka), Gabriele Lomas (UK), Silke Ludwig (Switzerland), Luis Nasi (Brazil), Fatos Olldashi (Albania), Patrick Plunkett (Ireland), Ian Roberts (UK), Peter Sandercock (UK), Haleema Shakur (UK), Caridad Soler (Cuba), Reto Stocker (Switzerland), Petr Svoboda (Czech Republic), Stefan Trenkler (Slovakia), N K Venkataramana (India), Jonathan Wasserberg (UK), David Yates (UK), Surakrant Yutthakasemsunt (Thailand).

Conflict of interest statement
The members of the writing committee declare that we have no conflict of interest.

Acknowledgments
Central randomisation and statistical support was provided by Clinical Trial Service Unit, Oxford, UK. The trial was funded by the UK Medical Research Council. Pharmacia & Upjohn (Pfizer from 2003) provided the Medical Research Council (without charge) the methylprednisolone needed for the trial, a grant-in-aid for preparation of the placebo, and support for collaborators’ meetings. The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

References